Narmac

Yes, we must be very patient now. Fall is not here yet and this trial is slow to roll out. Forthcoming are the trial start, the orphan indication, continued roll out to the scientific community, the Yale Club presentation, annual shareholders meeting, possible FDA news.... Why did DM express an interest in a Nasdaq listing? A higher share price puts the company in a much more stable and favorable growth position. This company is vulnerable right now and needs to get it over the top. Higher share price will enable key employee retention, attraction of executive talent, a possible foray into manufacturing, pursuit of other compounds and additional trials, protection from a hostile acquisition...If the street sees an opportunity here they will seize it and we will be running.

I agree that this may take a while longer, but we are on the cusp of something really big and those who wait will be rewarded.

Chicagoest